News Agency
The Times

Keymed Biosciences Announces Interim Results for First Half of 2024

  • Written by PR Newswire

CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. 

Rapid development of our pipeline products

Stapokibart (CM310) (IL-4Rα antibody)

  • In June 2024, the long-term efficacy and safety data from the Phase III...

Read more: Keymed Biosciences Announces Interim Results for First Half of 2024

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion